SVA Sernova Corp

Sernova Corp. (TSX VENTURE:SVA), a clinical stage company developing medical
technologies for the long-term treatment of chronic debilitating metabolic
diseases including diabetes and haemophilia is pleased to announce that it will
hold an annual general and special meeting of shareholders (the "AGM") on April
28, 2014. The record date for shareholders entitled to vote at the AGM is March
24, 2014.


The Company also announces that the board of directors of the Company (the
"Board") has approved and adopted By-Law No. 3 of the Company, being a by-law
relating to the nomination of directors of the Company (the "Advance Notice
By-Law) which requires that advance notice be provided to the Company in
circumstances where nominations of persons for election to the Board are made by
shareholders of the Company other than pursuant to: (i) a requisition of a
meeting of shareholders made pursuant to the provisions of the Canada Business
Corporations Act; or (ii) a shareholder proposal made pursuant to the provisions
of such Act.


"We feel the Advance Notice By-Law is an important corporate governance tool
that will ensure Sernova's shareholders are treated fairly in being provided
advanced notice of information in connection with the nomination of directors,"
said Dr. Philip Toleikis, President and CEO. 


The Advance Notice By-law is similar to the advance notice by-laws adopted by
many other Canadian public companies. The purpose is to foster a variety of
interests of the shareholders and the Company by ensuring that all shareholders,
including those participating in a meeting by proxy rather than in person,
receive adequate notice of the nominations to be considered at a meeting and can
thereby exercise their voting rights in an informed manner. In addition, the
Advance Notice By-Law should assist in facilitating an orderly and efficient
meeting process, provides shareholders, directors and management of the Company
with a clear framework for nominating directors. Among other things, the Advance
Notice by-Law fixes a deadline by which shareholders must submit director
nominations to the Company prior to any meeting of shareholders and sets forth
the minimum information that a shareholder must include in the notice to the
Company for the notice to be in proper written form.


In the case of an annual meeting of shareholders, notice to the Company must be
made not less than 30 nor more than 65 days prior to the date of the annual
meeting; provided, however that in the event the annual meeting is to be held on
a date that is less than 40 days after the date on which the first public
announcement of the date of the annual meeting was made, notice may be made not
later than the close of business on the 10th day following such public
announcement. 


In the case of a special meeting of shareholders (which is not also an annual
meeting), notice to the Company must be made not later than the close of
business on the 15th day following the day on which the first public
announcement of the date of the special meeting was made. 


The Advance Notice By-Law has been approved and adopted by the Board and is
effective immediately. Shareholders will be asked to ratify and confirm the
Advanced Notice By-Law at the AGM. A copy of the By-Law Amendments will be
provided in the Management Information Circular, which will be filed under the
Company's profile at www.sedar.com. 


For purposes of the AGM, in accordance with the terms of the Advance Notice
By-Law, notice of nominations of persons for election to the Board at the AGM
must be made by March 28, 2014 and be sent to the following email address of the
Chief Executive Officer of the Company: Philip.toleikis@sernova.com.


About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing
medical technologies for the treatment of chronic debilitating metabolic
diseases such as diabetes, blood disorders including haemophilia and other
diseases treated through replacement of proteins or hormones missing or in short
supply within the body. Sernova is developing the Cell Pouch(TM), an implantable
medical device for therapeutic cells (donor, xenogeneic or stem cells) which
then release proteins and/or hormones as required. The therapeutic cells are
protected from immune attack by Sernova's proprietary technology, Sertolin(TM). 


Forward-Looking Information 

This release may contain forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not always,
identified by the words "expects", "plans", "anticipates", "believes",
"intends", "estimates", "projects", "potential" and similar expressions, or that
events or conditions "will", "would", "may", "could" or "should" occur. Although
Sernova believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from those in
forward looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of Sernova's management on the date such statements were
made. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information,
future events or otherwise.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sernova Corp
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
philip.toleikis@sernova.com or info@sernova.com


Sernova Corp
Cathy Steiner
CFO
(416) 566-7870
cathy.steiner@sernova.com
www.sernova.com


Ray Matthews & Associates
Ray Matthews
(604) 818-7778
www.raymatthews.ca

Sernova (TSXV:SVA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Sernova (TSXV:SVA)
Historical Stock Chart
From Feb 2024 to Feb 2025